Peptides with in vitro and in vivo antitumor activity, source, cell biology and immunobiology
Bioactive peptides, with antitumor activity were found in internal sequences of immunoglobulins as well as in transcription factors. They are cytotoxic in human and murine cancer cells, they may inhibit tumor cell motility and invasion, affect the cell cycle and inhibit angiogenesis. Peptides derived from transcription factors act by competition or as agonists, and induce several cytotoxic effects in tumor cells and cells of the immune system. In vitro and in vivo antitumor protection mechanisms are investigated, some of them involving dendritic cell-dependent immune responses. The research line aims at the identification of these peptides, study of their mechanisms of action and the necessary modifications for their utilization in pre-clinical and clinical trials.
Recent publications (mainly in Experimental Oncology)
- Arruda DC, Santos LC, Melo FM, Pereira FV, Figueiredo CR, Matsuo AL, Mortara RA, Juliano MA, Rodrigues EG, Dobroff AS, Polonelli L, Travassos LR. b-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma. J Biol Chem. 2012; 287(18):14912-22.
- Matsuo AL, Juliano MA, Figueiredo CR, Batista WL, Tanaka AS, Travassos LR. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity. Mol Cancer Res. 2011; 9(11):1471-8.
- Scutti JA, Matsuo AL, Pereira FV, Massaoka MH, Figueiredo CR, Moreira DF, Belizário JE, Travassos LR. Role of SOCS-1 gene on melanoma cell growth and tumor development. Transl Oncol. 2011; 4(2):101-9.
- Dobroff AS, Rodrigues EG, Juliano MA, Friaça DM, Nakayasu ES, Almeida IC, Mortara RA, Jacysyn JF, Amarante-Mendes GP, Magliani W, Conti S, Polonelli L, Travassos LR. Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells.. Transl Oncol. 2010; 3(4):204-17.
- Dias BR, Rodrigues EG, Nimrichter L, Nakayasu ES, Almeida IC, Travassos LR. Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3. Mol Cancer. 2009; 8:116.